USP15
Gene Ontology Biological Process
- BMP signaling pathway [IDA]
- histone H2B conserved C-terminal lysine deubiquitination [IDA]
- monoubiquitinated protein deubiquitination [IDA]
- negative regulation of transforming growth factor beta receptor signaling pathway [TAS]
- pathway-restricted SMAD protein phosphorylation [IMP]
- proteasome-mediated ubiquitin-dependent protein catabolic process [IBA]
- protein deubiquitination [IDA]
- regulation of proteasomal protein catabolic process [IBA]
- transforming growth factor beta receptor signaling pathway [IDA, IMP, TAS]
Gene Ontology Molecular Function
PLA2G2A
Gene Ontology Biological Process
- defense response to Gram-positive bacterium [TAS]
- glycerophospholipid biosynthetic process [TAS]
- low-density lipoprotein particle remodeling [TAS]
- phosphatidic acid biosynthetic process [TAS]
- phosphatidic acid metabolic process [IDA]
- phosphatidylcholine acyl-chain remodeling [TAS]
- phosphatidylethanolamine acyl-chain remodeling [TAS]
- phosphatidylglycerol acyl-chain remodeling [TAS]
- phosphatidylinositol acyl-chain remodeling [TAS]
- phosphatidylserine acyl-chain remodeling [TAS]
- phospholipid metabolic process [IDA, TAS]
- positive regulation of inflammatory response [TAS]
- positive regulation of macrophage derived foam cell differentiation [TAS]
- small molecule metabolic process [TAS]
Gene Ontology Molecular Function
Gene Ontology Cellular Component
Biochemical Activity (Deubiquitination)
An interaction is inferred from the biochemical effect of one protein upon another, for example, GTP-GDP exchange activity or phosphorylation of a substrate by a kinase. The bait protein executes the activity on the substrate hit protein. A Modification value is recorded for interactions of this type with the possible values Phosphorylation, Ubiquitination, Sumoylation, Dephosphorylation, Methylation, Prenylation, Acetylation, Deubiquitination, Proteolytic Processing, Glucosylation, Nedd(Rub1)ylation, Deacetylation, No Modification, Demethylation.
Publication
Activity-based chemical proteomics accelerates inhibitor development for deubiquitylating enzymes.
Converting lead compounds into drug candidates is a crucial step in drug development, requiring early assessment of potency, selectivity, and off-target effects. We have utilized activity-based chemical proteomics to determine the potency and selectivity of deubiquitylating enzyme (DUB) inhibitors in cell culture models. Importantly, we characterized the small molecule PR-619 as a broad-range DUB inhibitor, and P22077 as a USP7 ... [more]
Throughput
- Low Throughput
Curated By
- BioGRID